A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses May 6, 2020 | COVID-19
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist. Apr 16, 2020 | Bladder Cancer, Merkel Cell Carcinoma, Non-Small Cell Lung Cancer
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. Oct 8, 2019 | Colorectal Cancer